Kestra Medical officer plans $144K stock sale

Officer Conor Hanley has filed a Rule 144 notice to sell 5,694 KMTS common shares acquired from vested equity awards.

Available on EDGAR 09/08/2026 - 04:15 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) received a notice that officer Conor Hanley plans to sell shares of its common stock under Rule 144. The notice covers 5,694 shares of common stock to be sold through Merrill Lynch on NASDAQ with an aggregate value of $143,778.46.

The shares relate to awards that vested on September 4, 2026, which were granted as part of the issuer’s equity compensation plan.

Key Figures

Shares to be sold: 5,694 shares Aggregate value: $143,778.46 Vesting date of RSU awards: September 4, 2026 +1 more

4 metrics

Shares to be sold 5,694 shares Common stock covered by the Rule 144 notice for planned sale

Aggregate value $143,778.46 Aggregate value of the 5,694 KMTS common shares listed for sale

Vesting date of RSU awards September 4, 2026 Date on which restricted stock unit awards vested

Planned sale date reference September 8, 2026 Date referenced in the securities information and signature sections

Key Terms

Rule 144, restricted stock unit awards, equity compensation plan

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock unit awards financial

"Vesting of restricted stock unit awards"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for KMTS?

It discloses that officer Conor Hanley has filed a notice under Rule 144 to sell 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. common stock, with an aggregate value of $143,778.46, through Merrill Lynch on NASDAQ.

How many KMTS shares are covered by Conor Hanley’s planned sale?

The notice covers 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. common stock to be sold. These shares are listed in the securities information section of the filing as the amount intended for sale under Rule 144.

What is the aggregate value of the KMTS shares in this Form 144?

The filing lists an aggregate value of $143,778.46 for the 5,694 shares of KMTS common stock covered by the planned Rule 144 sale through Merrill Lynch.

How did Conor Hanley acquire the KMTS shares to be sold?

The shares relate to the vesting of restricted stock unit awards on September 4, 2026. The filing states these awards were granted as part of the issuer equity compensation plan of KESTRA MEDICAL TECHNOLOGIES, LTD.

When are the KMTS awards associated with this Form 144 reported as vesting?

The filing states that the restricted stock unit awards vested on September 4, 2026. These vested awards under the issuer’s equity compensation plan are the source of the shares covered by the planned Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002072296
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Hanley Conor
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	5694	143778.46	58602497	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/04/2026	Vesting of restricted stock unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			5694	09/04/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Conor Hanley
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)